Filtered By:
Source: Vaccine
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 53 results found since Jan 2013.
The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years
CONCLUSION: Modestly higher RZV coverage in US adults 50-59 years could reduce the clinical burden associated with HZ and may result in societal cost savings. These findings demonstrate the potential value of increasing RZV vaccination in this population.PMID:37541822 | DOI:10.1016/j.vaccine.2023.07.025
Source: Vaccine - August 4, 2023 Category: Allergy & Immunology Authors: David Singer Ahmed Salem Nikita Stempniewicz Siyu Ma Sara Poston Desmond Curran Source Type: research
Impacts of routine varicella vaccination program and COVID-19 pandemic on varicella and herpes zoster incidence and health resource use among children in Japan
CONCLUSIONS: Varicella incidence and healthcare resource use were largely affected by the routine immunization program and infection prevention measures against COVID-19, while these impacts on herpes zoster were relatively small. Our study indicates that immunization and infection prevention measures largely changed pediatric infectious disease practices.PMID:37400282 | DOI:10.1016/j.vaccine.2023.06.054
Source: Vaccine - July 3, 2023 Category: Allergy & Immunology Authors: Kazuhiro Uda Yusuke Okubo Mitsuru Tsuge Hirokazu Tsukahara Isao Miyairi Source Type: research
Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine
CONCLUSIONS: This large post-licensure study did not identify evidence of safety concerns for HepB-CpG compared to HepB-alum for immune-mediated diseases, HZ, or anaphylaxis.PMID:37308363 | DOI:10.1016/j.vaccine.2023.06.004
Source: Vaccine - June 12, 2023 Category: Allergy & Immunology Authors: Bradley Ackerson Lina S Sy Jeff Slezak Lei Qian Kristi Reynolds Runxin Huang Zendi Solano William Towner Sijia Qiu Sarah R Simmons Steven J Jacobsen Katia J Bruxvoort Source Type: research
Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data
This study quantifies RZV coverage and assesses predictors for RZV vaccination using a U.S. claims database. Univariate linear regression provided annual prevalence of RZV vaccination and multivariable logistic regression provided ORs and 95% CIs for associations between predictors and RZV vaccination. A total of 4,124,315 individuals (19,080,914 person-years) were included in this study. Since receiving FDA approval for the prevention of HZ, RZV coverage (of at least one dose) has reached approximately 17% within the eligible U.S. population by January 2021, although significant disparities between demographic groups were...
Source: Vaccine - May 7, 2023 Category: Allergy & Immunology Authors: Chad Y Lewis Kunal Mishra Yuwei Sun Samantha J Sechrist Benjamin F Arnold Nisha R Acharya Source Type: research
Willingness to get vaccinated against influenza, pneumococcal disease, pertussis, and herpes zoster - A pre-COVID-19 exploration among the older adult population
CONCLUSIONS: Older adults were generally more willing to get vaccinated against influenza than for the three less familiar diseases. Characteristics of those less willing may be used to improve strategies to increase vaccination coverage. Additional studies are needed to investigate the willingness to get vaccinated during and after the COVID-19 pandemic that may have changed the feel of urgency for vaccination.PMID:36639273 | PMC:PMC9810548 | DOI:10.1016/j.vaccine.2023.01.001
Source: Vaccine - January 13, 2023 Category: Allergy & Immunology Authors: K M Maertzdorf M L Rietman M S Lambooij W M M Verschuren H S J Picavet Source Type: research
Impact of patient and provider nudges on addressing herpes zoster vaccine series completion
Vaccine. 2022 Dec 14:S0264-410X(22)01530-4. doi: 10.1016/j.vaccine.2022.12.016. Online ahead of print.NO ABSTRACTPMID:36526504 | DOI:10.1016/j.vaccine.2022.12.016
Source: Vaccine - December 16, 2022 Category: Allergy & Immunology Authors: Justin Gatwood Andrea Brookhart Olivia Kinney Tracy Hagemann Chi-Yang Chiu Sujith Ramachandran Emily Gravlee Kenneth Hohmeier Source Type: research
Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions
Vaccine. 2022 Nov 29:S0264-410X(22)01329-9. doi: 10.1016/j.vaccine.2022.10.063. Online ahead of print.NO ABSTRACTPMID:36460534 | DOI:10.1016/j.vaccine.2022.10.063
Source: Vaccine - December 2, 2022 Category: Allergy & Immunology Authors: Keith M Sullivan Francis A Farraye Kevin L Winthrop David O Willer Peter Vink Fernanda Tavares-Da-Silva Source Type: research
Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States
CONCLUSIONS: RZV uptake was low in the two years since the CDC recommendation, and differed by demographic, healthcare access, and clinical characteristics. Initiation rates were higher among immunocompromised adults compared to immunocompetent adults, despite no CDC recommendation for vaccination in these groups during the study period. The CDC has since recommended RZV for immunocompromised individuals, and our findings may inform efforts to increase RZV uptake in individuals at higher risk of severe disease.PMID:36396511 | DOI:10.1016/j.vaccine.2022.10.076
Source: Vaccine - November 17, 2022 Category: Allergy & Immunology Authors: Jonathan Fix Nadja A Vielot Jennifer L Lund David J Weber Jennifer S Smith Michael G Hudgens Sylvia Becker-Dreps Source Type: research
